Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study
Irinotecan, TAS-102 plus bevacizumab regimen preliminarily demonstrated promising efficacy with tolerable toxicity for mCRC patients as later-line treatment. This regimen warrants further exploration in refractory mCRC patients.
Authors
- Guifu Wu (ORCID: https://orcid.org/0000-0002-2823-6643)
- Wenwei Yang (ORCID: https://orcid.org/0000-0002-7292-5980)
- Yongkun Sun (ORCID: https://orcid.org/0000-0003-3302-6023)
- Deying Bi
- Baoqi Li (ORCID: https://orcid.org/0009-0002-5727-0573)
- Na Liu (ORCID: https://orcid.org/0000-0001-9705-2760)
- Tingting Yang (ORCID: https://orcid.org/0000-0002-5077-9900)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1038/s41416-024-02885-3
- Citations
- 4
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Cancer Foundation of China